BioLamina and Novo Nordisk Partner to Advance Stem Cell Based Therapies for Three Common Medical Conditions

Stockholm (ots/PRNewswire) -

BioLamina and collaborators have partnered with Novo Nordisk A/S
(Novo Nordisk), a Danish multinational pharmaceutical company,
allowing Novo Nordisk to develop novel stem cell based therapies
based on Biolaminins, human recombinant laminin cell culture
matrices, developed and produced by BioLamina.

Novo Nordisk have announced today that they are increasing their
commitment to cell therapies, including areas outside of diabetes.
The three cell therapy projects they have licensed are all based on
BioLamina technology. These projects aim to treat Parkinson's
disease, heart failure and loss of vision, all severe chronic
conditions.

Malin Parmar's research group at Lund University and Karl
Tryggvason's research group at Duke-NUS in Singapore have developed
potential cell therapies based on BioLamina's unique Biolaminin
matrices. Both groups have signed research and potential licensing
agreements with Novo Nordisk with the aim to develop these projects
further together with Novo Nordisk, enabling a translation of cell
therapy pre-clinical studies, to clinical trials and eventually
towards patient treatments.

The timing for these licensing agreements coincides well with the
launch of BioLamina's first cell therapy grade product a couple of
weeks ago, assuring cell therapy developers worldwide that
Biolamina's products can be used all the way from the bench to
bedside. There is an ongoing trend that researchers using embryonic
stem cell or induced pluripotent based protocols want to use
BioLamina products in their product development to make their
processes more robust and reproducible.

"There is a high demand for BioLamina's products in the
development of safe and robust cell-based therapies," says Kristian
Tryggvason, CEO for BioLamina, and continues "It is really intriguing
to see how Biolaminins are being part of building new therapies and
can help contribute treating many people in the future."

ABOUT BIOLAMINA AB

BioLamina commercializes innovations based on research from the
Karl Tryggvason laboratory at Karolinska Institute and Duke-NUS
solving technical problems within culturing of embryonic stem cells
and other types of primary cells. Many of the products manufactured
and sold by BioLamina are based on human recombinant proteins called
laminins. The laminins provide cells with an environment mimicking
their natural location in the cell culture dish. Different laminin
isoforms are expressed in different tissues in the body, hence many
different cell types can thrive on laminins. Laminins and other
innovations together solve many of the technical problems in research
such as reproducibility and low cell quality and therefore help the
development of new cell therapies. BioLamina was founded in 2009.

ots Originaltext: BioLamina AB
Im Internet recherchierbar: http://www.presseportal.de

Contact:
, please contact:
BIOLAMINA AB
Kristian Tryggvason, CEO Telephone +46-70-743-2233
E-mail: communications@biolamina.com

Original-Content von: BioLamina AB, übermittelt durch news aktuell